Positive data from clinical trial

I found this article at ovariancancer.org. Thought everyone may be interested:

Nektar has positive data from ovarian cancer study
Nektar Therapeutics on Monday reported that early results from a trial of an experimental cancer drug suggest a slowing in the progression of ovarian cancer.

The results come from a mid-stage study of a drug candidate called NKTR-102. The company is testing the drug on women whose cancer has progressed despite treatment with platinum-based chemotherapy.

Nektar said women who took the drug every three weeks had a median survival of 21 weeks before their cancer began to progress again or the died. Women who took the drug once every two weeks had median survival of 12.2 weeks.

The company said currently approved drugs halt the progression of ovarian cancer for 9.1 weeks to 13.6 weeks.

Nektar said the results come from 39 women in the study. A total of 71 patients are involved in the study and full results are expected later this year. The company is also testing NKTR-102 as a treatment for cancers of the breast, colon, and cervix.


Read the full article at: ovariancancer.org